VUU Changes How We Watch Our Favorite Movies and TV Series
VUU has launched a brand new technology that delivers bonus material, unique content and sought-after trivia directly to viewers in real time as they are watching movies and TV shows. VUU’s unique platform integrates directly with streaming services to provide audiences with a vast amount of add-on information about actors, locations, music, behind-the-scenes trivia, product placements and fan-generated content.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200908005242/en/
CEO at Vuu, Christian A. Strømmen (Photo: Business Wire)
VUU first launched on the web in the Nordics through Danish TVOD service Blockbuster (owned by TDC Group). It had already soft-launched in 2019 with a stand-alone iOS app but is now ready to offer its unique value-added content service to streaming platforms, worldwide.
Christian Strømmen, CEO and one of the founders of VUU, believes that increased competition mean that streaming services have to offer audiences a much more engaging and immersive experience.
“ We know that audiences are craving extra material and more information on everything from actors, music, behind-the-scenes videos, products and especially filming locations. By gathering all this information in one place, and giving the audience answers to what is happening on their screens right then and there, VUU provides a service like no other ” says the VUU founder.
Some might point towards Amazon X-Ray as the industry standard in this area but according to Strømmen, Amazon provides only some of what audiences are looking for. And only on its own streaming platform, Amazon Prime Video.
“VUU really comes into its own where Amazon X-Ray stops” says Strømmen. “Amazon X-Ray provides only basic information whereas VUU gives you much more in-depth, engaging and interactive content.”
Christian Strømmen and his team are confident that they can challenge Amazon: “We have fantastic content, some of which is exclusively generated by our own content team. Add to this a huge amount of carefully curated web articles, podcasts and videos that go in-depth and behind the scenes, and we have so much more to offer to viewers.”
VUU collects information from a broad spectrum of sources, including directly from studios.
“We recently reached an agreement with NBCUniversal on delivering all their official bonus material to streaming services like Blockbuster, and we are currently working on deals with multiple international studios” explains Strømmen.
And whilst offering all this content synchronised with whatever you are watching is a unique feature, VUU’s content can just as easily be enjoyed before or after watching something.
“We know from research that viewers love to revisit, relive or simple learn more about their favorite TV show or movie. Whether you are interested in knowing if something actually happened, how something was filmed or whether you can go visit a filming location in real life, VUU can tell you” says Strømmen.
STAND-OUT USER EXPERIENCE
But VUU is not all about the viewers. Strømmen explains that for streaming companies and Video-On-Demand platforms, a richer user experience helps them stand out in a market that is getting more and more crowded.
With changing viewing habits and more choice for audiences, keeping and attracting new users is no longer just about being able to offer the latest releases. Satisfying the viewer’s curiosity about what is on their screens is just as important.
VUU IMPRESSES BLOCKBUSTER
Being able to provide answers about cast, music, filming locations and trivia in a way that means viewers don’t have to sift through endless websites, blogs or videos themselves, is a fantastic way to differentiate - an opportunity that Blockbuster quickly recognized.
“For a long time, we were looking for a partner that can deliver this kind of content, and we’re very excited about the partnership with VUU. We were impressed by VUU and they’ve clearly seen a potential in the trends where people want to know more about ‘their’ movies and series” says Casper Hald, CEO of Blockbuster Denmark.
READY FOR MORE
Through Blockbuster’s service alone, VUU will be available on close to a million screens. But VUU has its sights set on more than Scandinavia alone: with the launch of so many new streaming services, across Europe and the US, VUU is ready for the international streaming market.
As Strømmen says: “With our flexible and easy-to-integrate technology, plus our industry-leading library of carefully curated and unique VUU-generated content for more than 2000 titles, we simply cannot wait to give audiences the world over a better viewing experience.”
For more info or to request an interview, please contact CEO Christian A. Strømmen
+ 47 91143948
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 13:55:00 EEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new
Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95
Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 10:30:00 EEST | Press release
Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu
Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 09:00:00 EEST | Press release
Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price
ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 08:00:00 EEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel ® (lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatm
Vifor Pharma Group Announces Successful Sale of OM Pharma18.9.2020 08:00:00 EEST | Press release
Regulatory News: Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal include: A purchase consideration of MCHF 435 for 100% of the share capital An earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity to be determined before the end of 2027 upon a trade sale, IPO or EBITDA multiple This earn out together with the purchase consideration could result in a total transaction value exceeding MCHF 500. The deal is expected to close within 30 days. OM Pharma is a Geneva-based company mainly active in the field of microbial derived immunotherapeutics and has developed strongly outside the core strategy of Vifor Pharma over the past few years. Optimus Holding Ltd. is a Swiss Group, founded by Etienne Jornod together with long-standing Swiss entrepreneurs and Abdi Ibrahim (28.5%), a Turkey-based pharmaceutical company operating in 12 countries a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom